 Jeffrey Olson
Concepts (319)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitreous Body | 14 | 2020 | 118 | 2.710 |
Why?
| | Ophthalmologic Surgical Procedures | 5 | 2017 | 91 | 1.910 |
Why?
| | Angiogenesis Inhibitors | 11 | 2022 | 239 | 1.810 |
Why?
| | Retina | 11 | 2016 | 331 | 1.510 |
Why?
| | Eye Foreign Bodies | 5 | 2016 | 23 | 1.460 |
Why?
| | Alloys | 4 | 2013 | 37 | 1.440 |
Why?
| | Glaucoma | 4 | 2017 | 253 | 1.430 |
Why?
| | Macular Edema | 4 | 2022 | 49 | 1.400 |
Why?
| | Retinal Detachment | 6 | 2019 | 74 | 1.370 |
Why?
| | Vitrectomy | 7 | 2019 | 74 | 1.330 |
Why?
| | Glaucoma Drainage Implants | 3 | 2016 | 47 | 1.270 |
Why?
| | Diabetic Retinopathy | 6 | 2019 | 211 | 1.260 |
Why?
| | Retinal Diseases | 5 | 2017 | 101 | 1.110 |
Why?
| | Intraocular Pressure | 7 | 2017 | 332 | 1.100 |
Why?
| | Nanopores | 2 | 2020 | 11 | 1.090 |
Why?
| | Membranes, Artificial | 2 | 2020 | 68 | 1.060 |
Why?
| | Intravitreal Injections | 7 | 2022 | 73 | 1.060 |
Why?
| | Nanotechnology | 2 | 2020 | 114 | 1.010 |
Why?
| | Suction | 3 | 2015 | 32 | 0.930 |
Why?
| | Sutures | 3 | 2015 | 66 | 0.870 |
Why?
| | Anterior Eye Segment | 2 | 2017 | 10 | 0.860 |
Why?
| | Choroidal Neovascularization | 4 | 2011 | 56 | 0.860 |
Why?
| | Swine | 10 | 2017 | 828 | 0.840 |
Why?
| | Suture Techniques | 3 | 2015 | 138 | 0.830 |
Why?
| | Equipment Design | 6 | 2017 | 527 | 0.820 |
Why?
| | Lens Implantation, Intraocular | 2 | 2015 | 80 | 0.790 |
Why?
| | Retinitis | 1 | 2022 | 21 | 0.730 |
Why?
| | Retinal Vasculitis | 1 | 2022 | 12 | 0.720 |
Why?
| | Aneurysm | 1 | 2022 | 37 | 0.710 |
Why?
| | Vitreoretinopathy, Proliferative | 2 | 2019 | 15 | 0.670 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2020 | 552 | 0.660 |
Why?
| | Antibodies, Monoclonal | 6 | 2020 | 1514 | 0.640 |
Why?
| | Durapatite | 1 | 2020 | 37 | 0.630 |
Why?
| | Retinal Vessels | 2 | 2015 | 79 | 0.620 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 22 | 0.610 |
Why?
| | Isoxazoles | 2 | 2013 | 56 | 0.610 |
Why?
| | Eye Injuries, Penetrating | 3 | 2016 | 19 | 0.610 |
Why?
| | Immunosuppressive Agents | 3 | 2013 | 840 | 0.610 |
Why?
| | Scleral Buckling | 3 | 2012 | 16 | 0.610 |
Why?
| | Endophthalmitis | 2 | 2017 | 46 | 0.600 |
Why?
| | Complement System Proteins | 2 | 2020 | 320 | 0.600 |
Why?
| | Disease Models, Animal | 8 | 2020 | 4604 | 0.580 |
Why?
| | Stents | 2 | 2013 | 570 | 0.550 |
Why?
| | Fluorocarbons | 2 | 2012 | 122 | 0.540 |
Why?
| | Glucocorticoids | 2 | 2020 | 537 | 0.510 |
Why?
| | Anterior Chamber | 1 | 2017 | 26 | 0.510 |
Why?
| | Transducers | 1 | 2017 | 27 | 0.510 |
Why?
| | Sclera | 2 | 2015 | 38 | 0.480 |
Why?
| | Strabismus | 1 | 2017 | 71 | 0.480 |
Why?
| | Filtering Surgery | 1 | 2016 | 23 | 0.480 |
Why?
| | Surgical Instruments | 2 | 2013 | 51 | 0.470 |
Why?
| | Trabeculectomy | 1 | 2017 | 75 | 0.470 |
Why?
| | Fovea Centralis | 2 | 2006 | 24 | 0.460 |
Why?
| | Retinal Perforations | 2 | 2005 | 18 | 0.450 |
Why?
| | Drug Resistance, Multiple, Viral | 2 | 2013 | 10 | 0.450 |
Why?
| | Ocular Hypertension | 1 | 2016 | 71 | 0.450 |
Why?
| | Lenses, Intraocular | 1 | 2015 | 49 | 0.440 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 290 | 0.440 |
Why?
| | Lasers | 1 | 2015 | 128 | 0.430 |
Why?
| | Laser Therapy | 1 | 2017 | 146 | 0.430 |
Why?
| | Ophthalmology | 2 | 2013 | 121 | 0.430 |
Why?
| | Prostheses and Implants | 1 | 2016 | 137 | 0.420 |
Why?
| | Device Removal | 1 | 2016 | 149 | 0.420 |
Why?
| | Ischemia | 2 | 2017 | 424 | 0.410 |
Why?
| | Antiviral Agents | 2 | 2013 | 776 | 0.400 |
Why?
| | Rabbits | 3 | 2020 | 654 | 0.400 |
Why?
| | Tomography, Optical Coherence | 7 | 2015 | 275 | 0.400 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 196 | 0.400 |
Why?
| | Fluorescein Angiography | 9 | 2012 | 193 | 0.390 |
Why?
| | Retinal Degeneration | 2 | 2015 | 40 | 0.390 |
Why?
| | Artificial Lens Implant Migration | 1 | 2013 | 3 | 0.380 |
Why?
| | Viscosupplements | 1 | 2012 | 11 | 0.380 |
Why?
| | Gravitation | 1 | 2012 | 22 | 0.380 |
Why?
| | Choroid | 3 | 2015 | 80 | 0.370 |
Why?
| | Silicon | 1 | 2012 | 19 | 0.370 |
Why?
| | Animals | 18 | 2020 | 38410 | 0.370 |
Why?
| | Pupil Disorders | 1 | 2012 | 7 | 0.370 |
Why?
| | Eye Enucleation | 1 | 2012 | 16 | 0.370 |
Why?
| | Iris | 1 | 2012 | 23 | 0.370 |
Why?
| | Macular Degeneration | 6 | 2015 | 196 | 0.370 |
Why?
| | Quantum Dots | 1 | 2012 | 37 | 0.360 |
Why?
| | Silicone Oils | 1 | 2012 | 38 | 0.360 |
Why?
| | Silicone Elastomers | 1 | 2012 | 7 | 0.360 |
Why?
| | Viremia | 1 | 2013 | 160 | 0.360 |
Why?
| | Uveitis, Posterior | 1 | 2012 | 12 | 0.360 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 156 | 0.360 |
Why?
| | Surgical Stapling | 1 | 2012 | 15 | 0.350 |
Why?
| | Electric Stimulation Therapy | 1 | 2012 | 63 | 0.350 |
Why?
| | Fluocinolone Acetonide | 1 | 2012 | 15 | 0.350 |
Why?
| | Vitreous Hemorrhage | 2 | 2015 | 10 | 0.350 |
Why?
| | Cataract Extraction | 1 | 2013 | 120 | 0.340 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2011 | 78 | 0.340 |
Why?
| | Models, Biological | 4 | 2015 | 1772 | 0.330 |
Why?
| | Materials Testing | 1 | 2012 | 346 | 0.310 |
Why?
| | Cytomegalovirus | 2 | 2013 | 172 | 0.300 |
Why?
| | Oxygen | 1 | 2015 | 998 | 0.290 |
Why?
| | Humans | 47 | 2022 | 147293 | 0.280 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 481 | 0.270 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.270 |
Why?
| | Biocompatible Materials | 1 | 2012 | 432 | 0.260 |
Why?
| | Electroretinography | 5 | 2016 | 51 | 0.260 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.250 |
Why?
| | Pigment Epithelium of Eye | 2 | 2006 | 36 | 0.250 |
Why?
| | Injections | 5 | 2012 | 200 | 0.240 |
Why?
| | Puerperal Disorders | 1 | 2007 | 36 | 0.240 |
Why?
| | Drug Implants | 2 | 2020 | 83 | 0.240 |
Why?
| | Recombinant Fusion Proteins | 4 | 2022 | 669 | 0.240 |
Why?
| | Uveal Diseases | 1 | 2006 | 6 | 0.240 |
Why?
| | Ocular Hypotension | 1 | 2006 | 10 | 0.240 |
Why?
| | Fusobacterium Infections | 1 | 2006 | 7 | 0.240 |
Why?
| | Pharyngeal Diseases | 1 | 2006 | 17 | 0.230 |
Why?
| | Epiretinal Membrane | 1 | 2005 | 7 | 0.230 |
Why?
| | Needles | 2 | 2017 | 63 | 0.230 |
Why?
| | Ciliary Body | 1 | 2006 | 40 | 0.230 |
Why?
| | Telangiectasis | 1 | 2005 | 7 | 0.230 |
Why?
| | Rats, Inbred BN | 3 | 2011 | 56 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2015 | 1005 | 0.220 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 3 | 2022 | 109 | 0.220 |
Why?
| | Uveitis | 1 | 2006 | 151 | 0.220 |
Why?
| | Visual Acuity | 7 | 2019 | 498 | 0.210 |
Why?
| | Injections, Intraocular | 2 | 2015 | 14 | 0.210 |
Why?
| | Kidney Transplantation | 2 | 2013 | 732 | 0.210 |
Why?
| | Dementia | 2 | 2022 | 332 | 0.210 |
Why?
| | Polypropylenes | 2 | 2015 | 12 | 0.210 |
Why?
| | Female | 26 | 2022 | 80076 | 0.200 |
Why?
| | Optic Atrophy | 1 | 2022 | 8 | 0.180 |
Why?
| | Hearing Loss, Central | 1 | 2022 | 6 | 0.180 |
Why?
| | Bevacizumab | 6 | 2015 | 168 | 0.180 |
Why?
| | Laser Coagulation | 3 | 2012 | 80 | 0.180 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 471 | 0.180 |
Why?
| | Middle Aged | 17 | 2019 | 36821 | 0.180 |
Why?
| | Retinal Vein Occlusion | 2 | 2015 | 14 | 0.170 |
Why?
| | Cell Count | 2 | 2012 | 321 | 0.170 |
Why?
| | Rats | 4 | 2012 | 5613 | 0.170 |
Why?
| | Dialysis | 1 | 2020 | 19 | 0.160 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2000 | 10 | 0.160 |
Why?
| | Orbital Neoplasms | 1 | 2000 | 28 | 0.160 |
Why?
| | Adsorption | 1 | 2020 | 154 | 0.150 |
Why?
| | Time Factors | 4 | 2017 | 7173 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2015 | 5476 | 0.150 |
Why?
| | Male | 21 | 2019 | 73950 | 0.140 |
Why?
| | Biomarkers | 2 | 2020 | 4351 | 0.140 |
Why?
| | Eye Diseases, Hereditary | 1 | 2018 | 15 | 0.140 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 36 | 0.140 |
Why?
| | Wet Macular Degeneration | 1 | 2019 | 63 | 0.140 |
Why?
| | Adult | 11 | 2022 | 41405 | 0.140 |
Why?
| | Miniaturization | 2 | 2015 | 22 | 0.140 |
Why?
| | Dextrans | 2 | 2009 | 84 | 0.130 |
Why?
| | Geographic Atrophy | 1 | 2019 | 101 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 849 | 0.130 |
Why?
| | Iris Diseases | 1 | 2017 | 7 | 0.130 |
Why?
| | Choroid Diseases | 1 | 2017 | 10 | 0.130 |
Why?
| | Hypertension | 1 | 2006 | 1280 | 0.130 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 1997 | 28 | 0.130 |
Why?
| | Dark Adaptation | 2 | 2012 | 13 | 0.130 |
Why?
| | Antimony | 1 | 2016 | 4 | 0.120 |
Why?
| | Infliximab | 2 | 2007 | 111 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2030 | 0.120 |
Why?
| | Pressure | 1 | 2017 | 228 | 0.120 |
Why?
| | Polymers | 1 | 2020 | 486 | 0.120 |
Why?
| | Sclerostomy | 1 | 2015 | 4 | 0.120 |
Why?
| | Foreign-Body Migration | 1 | 2016 | 33 | 0.110 |
Why?
| | Gyrate Atrophy | 1 | 2015 | 2 | 0.110 |
Why?
| | Aged, 80 and over | 6 | 2019 | 8430 | 0.110 |
Why?
| | Vitreoretinal Surgery | 1 | 2015 | 4 | 0.110 |
Why?
| | Equipment Failure Analysis | 1 | 2015 | 124 | 0.110 |
Why?
| | Vitreous Detachment | 1 | 2015 | 6 | 0.110 |
Why?
| | Partial Pressure | 1 | 2015 | 30 | 0.110 |
Why?
| | Hemoglobin SC Disease | 1 | 2015 | 14 | 0.110 |
Why?
| | Stress, Mechanical | 1 | 2017 | 494 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2016 | 127 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2015 | 186 | 0.110 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 55 | 0.110 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 46 | 0.110 |
Why?
| | Treatment Outcome | 9 | 2016 | 11947 | 0.110 |
Why?
| | Feedback | 1 | 2015 | 181 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2014 | 1431 | 0.110 |
Why?
| | International Normalized Ratio | 1 | 2014 | 56 | 0.100 |
Why?
| | Aged | 10 | 2020 | 26514 | 0.100 |
Why?
| | Protein Binding | 1 | 2020 | 2249 | 0.100 |
Why?
| | Oculomotor Muscles | 1 | 2014 | 86 | 0.100 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1049 | 0.100 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2013 | 19 | 0.100 |
Why?
| | Retinal Artery Occlusion | 1 | 2013 | 10 | 0.100 |
Why?
| | Tendons | 1 | 2014 | 134 | 0.100 |
Why?
| | Down Syndrome | 1 | 2000 | 526 | 0.100 |
Why?
| | Postoperative Care | 1 | 2015 | 299 | 0.100 |
Why?
| | Specific Gravity | 1 | 2012 | 13 | 0.090 |
Why?
| | Transducers, Pressure | 1 | 2012 | 12 | 0.090 |
Why?
| | Warfarin | 1 | 2014 | 179 | 0.090 |
Why?
| | Adaptation, Ocular | 1 | 2012 | 6 | 0.090 |
Why?
| | Rats, Mutant Strains | 1 | 2012 | 19 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2012 | 2627 | 0.090 |
Why?
| | Viscosity | 1 | 2012 | 92 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1157 | 0.090 |
Why?
| | Erythrocyte Transfusion | 1 | 2015 | 225 | 0.090 |
Why?
| | Minerals | 1 | 2012 | 48 | 0.090 |
Why?
| | Acetates | 1 | 2012 | 78 | 0.090 |
Why?
| | Pupil | 1 | 2012 | 22 | 0.090 |
Why?
| | Metabolomics | 1 | 2018 | 736 | 0.090 |
Why?
| | Corneal Endothelial Cell Loss | 1 | 2012 | 3 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2231 | 0.090 |
Why?
| | Sodium Chloride | 1 | 2012 | 138 | 0.090 |
Why?
| | Endothelium, Corneal | 1 | 2012 | 19 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2007 | 1224 | 0.090 |
Why?
| | Retinal Neovascularization | 1 | 2012 | 29 | 0.090 |
Why?
| | Electrodes, Implanted | 1 | 2012 | 114 | 0.090 |
Why?
| | Swine, Miniature | 1 | 2012 | 89 | 0.090 |
Why?
| | Microsurgery | 1 | 2012 | 76 | 0.090 |
Why?
| | Gold | 1 | 2012 | 116 | 0.090 |
Why?
| | Bruch Membrane | 1 | 2011 | 6 | 0.090 |
Why?
| | Drug Combinations | 1 | 2012 | 399 | 0.080 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 44 | 0.080 |
Why?
| | Retinal Ganglion Cells | 1 | 2012 | 123 | 0.080 |
Why?
| | Adolescent | 4 | 2019 | 22825 | 0.080 |
Why?
| | Administration, Oral | 1 | 2013 | 874 | 0.080 |
Why?
| | Drug Compounding | 1 | 2011 | 107 | 0.080 |
Why?
| | Dissection | 1 | 2011 | 58 | 0.080 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 191 | 0.080 |
Why?
| | Computer Simulation | 1 | 2015 | 1018 | 0.080 |
Why?
| | Models, Animal | 1 | 2012 | 394 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2434 | 0.080 |
Why?
| | Bacteria | 1 | 2015 | 769 | 0.070 |
Why?
| | Lactic Acid | 1 | 2011 | 295 | 0.070 |
Why?
| | Cell Survival | 1 | 2012 | 1111 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2013 | 322 | 0.070 |
Why?
| | Retrospective Studies | 8 | 2015 | 17560 | 0.070 |
Why?
| | Scotoma | 1 | 2008 | 6 | 0.070 |
Why?
| | Atrial Fibrillation | 1 | 2014 | 560 | 0.070 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2007 | 48 | 0.070 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2007 | 31 | 0.060 |
Why?
| | Papilledema | 1 | 2007 | 44 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2973 | 0.060 |
Why?
| | RNA, Catalytic | 1 | 2007 | 191 | 0.060 |
Why?
| | Visual Fields | 3 | 2007 | 116 | 0.060 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 21 | 0.060 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2006 | 27 | 0.060 |
Why?
| | Triamcinolone Acetonide | 1 | 2006 | 20 | 0.060 |
Why?
| | Fusobacterium necrophorum | 1 | 2006 | 2 | 0.060 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 649 | 0.060 |
Why?
| | Pilot Projects | 1 | 2012 | 1912 | 0.060 |
Why?
| | Vision, Low | 3 | 2013 | 16 | 0.060 |
Why?
| | Indocyanine Green | 1 | 2005 | 43 | 0.060 |
Why?
| | Myopia | 1 | 2006 | 59 | 0.060 |
Why?
| | Coloring Agents | 1 | 2005 | 90 | 0.060 |
Why?
| | Eye Injuries | 1 | 2006 | 53 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2005 | 153 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 430 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 385 | 0.050 |
Why?
| | Young Adult | 2 | 2019 | 14437 | 0.050 |
Why?
| | Cataract | 1 | 2006 | 238 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1550 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1518 | 0.050 |
Why?
| | Ranibizumab | 2 | 2013 | 21 | 0.040 |
Why?
| | Blindness | 2 | 2013 | 51 | 0.040 |
Why?
| | Exophthalmos | 1 | 2000 | 18 | 0.040 |
Why?
| | Keratitis | 1 | 2000 | 21 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1844 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2000 | 325 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2012 | 3022 | 0.040 |
Why?
| | Xanthine | 1 | 2018 | 7 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2791 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1281 | 0.030 |
Why?
| | Electrooculography | 1 | 1997 | 13 | 0.030 |
Why?
| | Color Vision Defects | 1 | 1997 | 8 | 0.030 |
Why?
| | Visual Field Tests | 1 | 1997 | 32 | 0.030 |
Why?
| | Purines | 1 | 2018 | 188 | 0.030 |
Why?
| | Fundus Oculi | 1 | 1997 | 89 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1084 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 6099 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1997 | 266 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.030 |
Why?
| | Child | 2 | 2015 | 22979 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 90 | 0.030 |
Why?
| | Endotamponade | 1 | 2015 | 3 | 0.030 |
Why?
| | Vision Disorders | 1 | 1997 | 179 | 0.030 |
Why?
| | Myopia, Degenerative | 1 | 2015 | 5 | 0.030 |
Why?
| | Tenon Capsule | 1 | 2014 | 3 | 0.030 |
Why?
| | Tissue Adhesions | 1 | 2015 | 34 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 728 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 391 | 0.030 |
Why?
| | Photography | 1 | 2015 | 120 | 0.030 |
Why?
| | Conjunctiva | 1 | 2014 | 52 | 0.030 |
Why?
| | Biometry | 1 | 2014 | 66 | 0.030 |
Why?
| | Atrophy | 1 | 2015 | 201 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2890 | 0.030 |
Why?
| | Pregnancy | 1 | 2007 | 7274 | 0.020 |
Why?
| | Glucose | 1 | 2018 | 1051 | 0.020 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2014 | 145 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 11017 | 0.020 |
Why?
| | Retreatment | 1 | 2012 | 80 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 975 | 0.020 |
Why?
| | Risk Assessment | 2 | 2014 | 3784 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2018 | 1368 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1386 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1344 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 406 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3216 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 428 | 0.020 |
Why?
| | Antioxidants | 1 | 2014 | 550 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 448 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2009 | 75 | 0.020 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2009 | 50 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1672 | 0.020 |
Why?
| | Anticoagulants | 1 | 2014 | 751 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4591 | 0.020 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2007 | 122 | 0.020 |
Why?
| | Prospective Studies | 2 | 2012 | 8164 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2006 | 32 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 32 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2007 | 253 | 0.010 |
Why?
| | Infant | 1 | 2000 | 10194 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4383 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 487 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1940 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2007 | 2080 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2812 | 0.010 |
Why?
| | Aging | 1 | 2008 | 1992 | 0.010 |
Why?
|
|
Olson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|